(Reuters) -GSK on Tuesday agreed to buy U.S. biotech Affinivax for up to $3.3 billion, its second major deal in two months, giving the British pharmaceutical giant access to the company's roster of ...
GSK plc GSK announced that it has entered into a definitive agreement with Massachusetts-based privately held biopharmaceutical company, Affinivax, Inc., wherein it will acquire the latter for an ...
GlaxoSmithKline on Wednesday lifted its long-term outlook following the smash-hit launch of its new RSV vaccine. The shot targeting the severe and in some cases life-threatening virus booked around £1 ...
GSK on Tuesday upped its 2024 profit guidance, as surging sales of its HIV drugs and recently launched shingles vaccine saw it beat analyst expectations in the first quarter of the year. The FTSE-100 ...
The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE:GSK), Sanofi SA (NASDAQ:SNY) and Australian firm CSL Limited (OTC:CSLLY) to more than double the U.S. supply of bird ...
LONDON (Reuters) -GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit growth, lifting the British company's shares by nearly 7% to ...
Rates of vaccination in the U.S. have dropped in recent years, with the COVID-19 pandemic hitting uptake. GSK, with a new vaccine to market, is looking to help turn this around. GSK is running a new ...
GlaxoSmithKline on Wednesday lifted its long-term outlook following the smash-hit launch of its new RSV vaccine last year. The shot, called Arexvy, booked £1.2 billion ($1.5 billion) in sales after ...
(Reuters) - GSK on Tuesday agreed to buy U.S. biotech Affinivax for up to $3.3 billion, its second major deal in two months, giving the British pharmaceutical giant access to the company's roster of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback